CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Oppose proposals to reduce data exclusivity Oppose proposals to restrict data uses Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics Support USTR resolution process with Mexico trade authority to allow biotech corn into Mexican market
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Defense DEF
Oppose domestic manufacturing/procurement mandates in NDAA for pharmaceutical products, APIs, & medical devices
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Banking BAN
Banking reform, Federal Reserve and Treasury oversight of regional banks
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Budget/Appropriations BUD
Labor/HHS/Ed Appropriations: Drug Pricing, FDA, NIH, biodefense/pandemic, CDC, science/math education, and strategic stockpile funding and preparation; Coronovirus funding and response FDA Appropriations; PTO Appropriations; eLabeling appropriations language. Drug Pricing proposals, Orphan Drug Tax Credit; semiconductor/CHIPS funding; oppose budget reconciliation with drug pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Health Issues HCR
Support FDA user fee programs and review process consistency and predictability. Support FDA modernization practices Support legislation proposing coverage for multi-cancer screening Support FDA modernization efforts and vaccine awareness Oppose domestic manufacturing/procurement mandates for pharmaceutical products, APIs, & medical devices Support improvements to the Strategic National Stockpile for pandemic testing preparedness Support public education campaign on pandemic preparedness Support re-authorization of Rare Pediatric Disease Priority Review Voucher (RPD PRV) program Oppose drug importation proposals Support diversity in clinical trial policy Support medical device change control plans legislation Oppose drug pricing proposals that allow Medicare to directly negotiate prices Support bipartisan Pandemics and All Hazards Preparedness Re-authorization Support alternatives to animal testing in trials Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Medicare/Medicaid MMM
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3 Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule, implementation, and legislation Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the elife sciences ecosystem Oppose drug importation proposals Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule regarding cost-sharing assistance Support capping Medicare beneficiary out of pocket costs Support expanded access to telehealth Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Taxation/Internal Revenue Code TAX
Support R&D and NOL tax incentives, Orphan Drug Tax Credits, repeal of R&D tax amortization
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Medical/Disease Research/Clinical Labs MED
Support NIH research funding Support implementation of 21st Century Cures Act Support promulgation of TCET rule Support alternatives to animal research Support breakthrough device coverage bill Support bipartisan PAHPA reauthorization
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Copyright/Patent/Trademark CPT
Address concerns with provisions of patent litigation reform, including inter-partes review Support STRONGER Patents Act Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic R&D Support incentives for onshore and near shore critical manufacturing capacities
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| ANTHONY THEISSEN New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.